Recent trends in antibody based sensors.

Biosens Bioelectron

Cranfield Health, Cranfield University, Cranfield, Bedfordshire, UK.

Published: April 2012

This review details recent advances in the fields of immunosensors and closely related immunoassays in the past decade, together with a discussion of possible future trends. Immunosensors can be classified by the way in which they transduce the signal produced upon the formation of an antibody antigen complex. Recent advancements to these methods of detection and transduction are discussed in detail, with particular focus on electrochemical, optical, piezoelectric and magnetic based sensors. The varying applications of these sensors are also discussed. Some of the most significant advances include development of immunosensors for the continuous monitoring of analytes, point of care (PoC) devices, with lower unit costs, automation, reusability and ease of use. Immunosensor technology has advanced at a prolific rate since its conception and has grown into a diverse area of ongoing research.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bios.2011.10.023DOI Listing

Publication Analysis

Top Keywords

based sensors
8
trends antibody
4
antibody based
4
sensors review
4
review details
4
details advances
4
advances fields
4
fields immunosensors
4
immunosensors closely
4
closely immunoassays
4

Similar Publications

Nanozyme-based colorimetric sensors are promising approaches for environmental monitoring, food safety, and medical diagnostics. However, developing novel nanozymes that exhibit high catalytic activity, good dispersion in aqueous solution, high sensitivity, selectivity, and stability is challenging. In this study, for the first time, single-atom iridium-doped carbon dot nanozymes (SA Ir-CDs) are synthesized via a simple in situ pyrolysis process.

View Article and Find Full Text PDF

Mechanical and thermal responsive chiral photonic cellulose hydrogels for dynamic anti-counterfeiting and optical skin.

Mater Horiz

January 2025

Key Laboratory of Bio-based Material Science and Technology of Ministry of Education, Northeast Forestry University, Harbin 150040, China.

Dynamic responsive structural colored materials have drawn increased consideration in a wide range of applications, such as colorimetric sensors and high-safety tags. However, the sophisticated interactions among the individual responsive parts restrict the advanced design of multimodal responsive photonic materials. Inspired by stimuli-responsive color change in chameleon skin, a simple and effective photo-crosslinking strategy is proposed to construct hydroxypropyl cellulose (HPC) based hydrogels with multiple responsive structured colors.

View Article and Find Full Text PDF

Flexible tactile sensors have received significant attention for use in wearable applications such as robotics, human-machine interfaces, and health monitoring. However, conventional tactile sensors face challenges in accurately measuring pressure because vertical deformation is induced by Poisson's ratio in situations where lateral strain is applied. This study shows a strain-insensitive flexible tactile sensor array without the crosstalk effect using a highly stretchable mesh.

View Article and Find Full Text PDF

Most traditional optical biosensors operate through molecular recognition, where ligand binding causes conformational changes that lead to optical perturbations in the emitting motif. Optical sensors developed from single-stranded DNA-functionalized single-walled carbon nanotubes (ssDNA-SWCNTs) have started to make useful contributions to biological research. However, the mechanisms underlying their function have remained poorly understood.

View Article and Find Full Text PDF

BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!